AI Article Synopsis
- - COVID-19 has a significant impact on long-term care facilities (LTCFs), resulting in high rates of illness and death.
- - Among fully vaccinated residents and staff in LTCFs, the vaccine showed an effectiveness of approximately 81.5% against infection.
- - The vaccine was particularly effective against severe outcomes, with a 93.1% effectiveness against death in residents, and no hospitalizations reported for fully vaccinated staff.
Article Abstract
Coronavirus disease 2019 (COVID-19) causes high morbidity and mortality in long-term care facilities (LTCFs). COVID-19 vaccine effectiveness against infection was 81.5% and 81.4% among fully vaccinated residents and staff in LTCFs. The vaccine effectiveness against COVID-19-associated death was 93.1% among residents, and no hospitalizations occurred among fully vaccinated staff.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615003 | PMC |
| http://dx.doi.org/10.1017/ash.2021.246 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
J Infect Dis
December 2024
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Background: The robustness and persistence of vaccine antigen-induced antibodies are often used as proxy indicators of vaccine efficacy, but immune responses to vaccine vectors are typically less well-defined. Our study considered the kinetics of immunoglobulin (IgG) responses against the vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and the inserted antigen (Ebola virus [EBOV]) glycoprotein (GP1,2) components of the rVSVΔG-ZEBOV-GP (rVSV-ZEBOV) vaccine and evaluated their use as biomarkers to confirm self-reported vaccination status.
Methods: From the Partnership for Research on Ebola Virus in Liberia (PREVAIL) I clinical trial (NCT02344407), we randomly selected 212 participants who received rVSV-ZEBOV (n=107) or placebo (n=105).
Oral Immunization of Mice with a Nonantibiotic Recombinant Coexpressing TsNd and gp43 Protein Vaccine Combined with a Murine Interleukin-33 Adjuvant.
Foodborne Pathog Dis
December 2024
College of Veterinary Medicine, Jilin Agricultural University, Changchun, China.
Trichinellosis, a zoonotic disease transmitted through food and caused by , is a significant health concern worldwide. Therefore, developing a safe and effective vaccine to combat infection is essential. In this study, a nonantibiotic strain lacking the gene served as a live bacterial vector to deliver antigens to the host, creating a novel oral vaccine.
View Article and Find Full Text PDFPersistence of HPV in cervical smears of vaccinated WLWH support for combined molecular testing and cytology screening.
Int J STD AIDS
December 2024
Virological Diagnostic Laboratory, Department of Microbiology and Parasitology, Biomedical Institute, Universidade Federal Fluminense, Niteroi, Brazil.
Background: Human papillomavirus (HPV) infection profoundly affects women living with HIV (WLWH). This infection leads to cervical cancer (CC) and increased mortality.
Methods: This study monitored HPV infection in WLWH in Rio de Janeiro, Brazil, before (T1) and after (T2) 4 years of vaccination.
Testing an HPV Vaccine Decision Aid for 27- to 45-Year-Old Adults in the United States: A Randomized Trial.
Med Decis Making
December 2024
Department of Social & Behavioral Sciences, College of Public Health, Temple University, Philadelphia, PA, USA.
Background: In the United States, human papillomavirus (HPV) vaccination among 27- to 45-y-olds (mid-adults) is recommended based on shared clinical decision making with a health care provider. We developed a patient decision aid tool to support the implementation of this mid-adult HPV vaccination guideline. The purpose of this study was to evaluate the effect of a patient decision aid tool for HPV vaccination, HPV DECIDE, compared with an information fact sheet among mid-adults who have not received the HPV vaccine.
View Article and Find Full Text PDFEpidemiological, molecular, and evolutionary characteristics of G1P[8] rotavirus in China on the eve of RotaTeq application.
Front Cell Infect Microbiol
December 2024
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Health Commission Key Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Introduction: This study, conducted in China prior to RotaTeq's launch, examined the epidemiological, molecular, and evolutionary features of the G1P[8] genotype RVA in children admitted with diarrhea, to aid in evaluating its efficacy and impact on G1P[8] RVA in China.
Methods: Data from the Chinese viral diarrhea surveillance network were collected from January 2016 to December 2018. RVA strains identified as the G1P[8] genotype were subjected to whole-genome sequencing.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!